Role of interleukin‐1, tumor necrosis factor α, and interleukin‐6 in cartilage proteoglycan metabolism and destruction effect of in situ blocking in murine antigen‐ and zymosan‐induced arthritis
Objective. To determine the involvement of interleukin‐1 (IL‐1), tumor necrosis factor (TNF), and IL‐6 in the cartilage pathology of murine antigen‐induced arthritis (AIA) and zymosan‐induced arthritis (ZIA). Methods. Arthritis was induced by intraarticular injection of zymosan in naive mice or by s...
Gespeichert in:
| Veröffentlicht in: | Arthritis and rheumatism 1995-02, Vol.38 (2), p.164-172 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 172 |
|---|---|
| container_issue | 2 |
| container_start_page | 164 |
| container_title | Arthritis and rheumatism |
| container_volume | 38 |
| creator | Loo, Fons A. J. Van De Joosten, Leo A. B. Van Lent, Peter L. E. M. Arntz, Onno J. Van Den Berg, Wim B. |
| description | Objective. To determine the involvement of interleukin‐1 (IL‐1), tumor necrosis factor (TNF), and IL‐6 in the cartilage pathology of murine antigen‐induced arthritis (AIA) and zymosan‐induced arthritis (ZIA).
Methods. Arthritis was induced by intraarticular injection of zymosan in naive mice or by subcutaneous injection of methylated bovine serum albumin in sensitized animals. Mini‐osmotic pumps releasing human recombinant IL‐1 receptor antagonist (IL‐1ra) protein were implanted intraperitoneally 2 days before arthritis induction, and neutralizing antibodies directed against murine IL‐1α, IL‐1β, TNFα, or IL‐6 were administered 1 day before. Proteoglycan (PG) synthesis and degradation were assessed in patellar cartilage.
Results. Murine IL‐1α and IL‐1β injected intraarticularly at doses of 0.1–100 ng suppressed chondrocyte PG synthesis. The highest dose of TNF tested (100 ng) decreased PG synthesis marginally. In contrast, the maximum dose of IL‐6 (1 μg) stimulated PG synthesis 2 days after injection. Treatment of AIA with neutralizing monoclonal antibodies against either TNFα or IL‐6 did not reduce either the PG degradation or the suppression of its synthesis. However, treatment with anti‐IL‐1 (α + β) polyclonal antibodies totally prevented PG suppression, although the initial breakdown of PG was unaffected. This effect was confirmed when IL‐1ra was administered in high doses. Moreover, treatment of ZIA with anti‐IL‐1 (α + β), but not with anti‐TNF, resulted in normal PG synthesis, confirming the key role played by IL‐1 in the inhibition of PG synthesis. Treatment of AIA with anti‐IL‐1 did not affect inflammation during the acute phase, but a significant reduction of ongoing inflammation was noted at day 7, and there was a marked reduction in the loss of cartilage PG.
Conclusion. The suppression of PG synthesis in both ZIA and AIA in mice is due to the combined local action of IL‐1 (α + β), and neither IL‐6 nor TNF is involved. Moreover, the normalization of PG synthesis brought about by blocking of IL‐1 ameliorates the cartilage damage associated with AIA. |
| doi_str_mv | 10.1002/art.1780380204 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_16720049</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16720049</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3554-85086740ab6ec0b266f6ae2749f643e1c964f5a19342c80c85f7a699dd7f70153</originalsourceid><addsrcrecordid>eNqFUctuFDEQHCFQWAJXbkg-IE6ZxR6_xsco4iVFQorCeeT1tBeDxw62R2g55RPyK3wHEh_Bl-DJrgLiwskqd1VXdXfTPCV4TTDuXupU1kT2mPa4w-xesyK8Uy0mlNxvVhhj1lKuyMPmUc6fKuwop0fNkexZT7FYNT8uogcULXKhQPIwf3bh1_UNOUFlnmJCAUyK2WVktSkV__x-gnQY_6GLipGpUZzXW0BXKRaIW78zOqAJit5E7_J0KxwhlzSb4mJAYC2YsndH2ZUZbXw0teV2-Zjm5AJUUXFbWFxu9d92U8x6gS6Ms4ERVduPyRWXHzcPrPYZnhze4-bD61eXZ2_b8_dv3p2dnreGcs7anuNeSIb1RoDBm04IKzR0kikrGAVilGCWa6Io60yPTc-t1EKpcZRWYsLpcfNi37fO-WWu8wyTywa81wHinAciZFcXrypxvScuO8wJ7HCV3KTTbiB4WK431OzDn-tVwbND53kzwXhHP5yr1p8f6job7W3Swbh8R6NMScmXgGpP--o87P5jOpxeXP4V4Tdyl7vX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16720049</pqid></control><display><type>article</type><title>Role of interleukin‐1, tumor necrosis factor α, and interleukin‐6 in cartilage proteoglycan metabolism and destruction effect of in situ blocking in murine antigen‐ and zymosan‐induced arthritis</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><creator>Loo, Fons A. J. Van De ; Joosten, Leo A. B. ; Van Lent, Peter L. E. M. ; Arntz, Onno J. ; Van Den Berg, Wim B.</creator><creatorcontrib>Loo, Fons A. J. Van De ; Joosten, Leo A. B. ; Van Lent, Peter L. E. M. ; Arntz, Onno J. ; Van Den Berg, Wim B.</creatorcontrib><description>Objective. To determine the involvement of interleukin‐1 (IL‐1), tumor necrosis factor (TNF), and IL‐6 in the cartilage pathology of murine antigen‐induced arthritis (AIA) and zymosan‐induced arthritis (ZIA).
Methods. Arthritis was induced by intraarticular injection of zymosan in naive mice or by subcutaneous injection of methylated bovine serum albumin in sensitized animals. Mini‐osmotic pumps releasing human recombinant IL‐1 receptor antagonist (IL‐1ra) protein were implanted intraperitoneally 2 days before arthritis induction, and neutralizing antibodies directed against murine IL‐1α, IL‐1β, TNFα, or IL‐6 were administered 1 day before. Proteoglycan (PG) synthesis and degradation were assessed in patellar cartilage.
Results. Murine IL‐1α and IL‐1β injected intraarticularly at doses of 0.1–100 ng suppressed chondrocyte PG synthesis. The highest dose of TNF tested (100 ng) decreased PG synthesis marginally. In contrast, the maximum dose of IL‐6 (1 μg) stimulated PG synthesis 2 days after injection. Treatment of AIA with neutralizing monoclonal antibodies against either TNFα or IL‐6 did not reduce either the PG degradation or the suppression of its synthesis. However, treatment with anti‐IL‐1 (α + β) polyclonal antibodies totally prevented PG suppression, although the initial breakdown of PG was unaffected. This effect was confirmed when IL‐1ra was administered in high doses. Moreover, treatment of ZIA with anti‐IL‐1 (α + β), but not with anti‐TNF, resulted in normal PG synthesis, confirming the key role played by IL‐1 in the inhibition of PG synthesis. Treatment of AIA with anti‐IL‐1 did not affect inflammation during the acute phase, but a significant reduction of ongoing inflammation was noted at day 7, and there was a marked reduction in the loss of cartilage PG.
Conclusion. The suppression of PG synthesis in both ZIA and AIA in mice is due to the combined local action of IL‐1 (α + β), and neither IL‐6 nor TNF is involved. Moreover, the normalization of PG synthesis brought about by blocking of IL‐1 ameliorates the cartilage damage associated with AIA.</description><identifier>ISSN: 0004-3591</identifier><identifier>EISSN: 1529-0131</identifier><identifier>DOI: 10.1002/art.1780380204</identifier><identifier>PMID: 7848306</identifier><identifier>CODEN: ARHEAW</identifier><language>eng</language><publisher>New York: John Wiley & Sons, Inc</publisher><subject>Animals ; Antibody Formation ; Antigens ; Arthritis - chemically induced ; Arthritis - etiology ; Arthritis - prevention & control ; Biological and medical sciences ; Cartilage, Articular - drug effects ; Cartilage, Articular - metabolism ; Cartilage, Articular - pathology ; Cytokines - immunology ; Diseases of the osteoarticular system ; Inflammatory joint diseases ; Interleukin-1 - physiology ; Interleukin-6 - physiology ; Male ; Medical sciences ; Mice ; Proteoglycans - biosynthesis ; Proteoglycans - metabolism ; Receptors, Interleukin-1 - antagonists & inhibitors ; Tumor Necrosis Factor-alpha - physiology ; Zymosan</subject><ispartof>Arthritis and rheumatism, 1995-02, Vol.38 (2), p.164-172</ispartof><rights>Copyright © 1995 American College of Rheumatology</rights><rights>1995 INIST-CNRS</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3554-85086740ab6ec0b266f6ae2749f643e1c964f5a19342c80c85f7a699dd7f70153</citedby><cites>FETCH-LOGICAL-c3554-85086740ab6ec0b266f6ae2749f643e1c964f5a19342c80c85f7a699dd7f70153</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fart.1780380204$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fart.1780380204$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3497755$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7848306$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Loo, Fons A. J. Van De</creatorcontrib><creatorcontrib>Joosten, Leo A. B.</creatorcontrib><creatorcontrib>Van Lent, Peter L. E. M.</creatorcontrib><creatorcontrib>Arntz, Onno J.</creatorcontrib><creatorcontrib>Van Den Berg, Wim B.</creatorcontrib><title>Role of interleukin‐1, tumor necrosis factor α, and interleukin‐6 in cartilage proteoglycan metabolism and destruction effect of in situ blocking in murine antigen‐ and zymosan‐induced arthritis</title><title>Arthritis and rheumatism</title><addtitle>Arthritis Rheum</addtitle><description>Objective. To determine the involvement of interleukin‐1 (IL‐1), tumor necrosis factor (TNF), and IL‐6 in the cartilage pathology of murine antigen‐induced arthritis (AIA) and zymosan‐induced arthritis (ZIA).
Methods. Arthritis was induced by intraarticular injection of zymosan in naive mice or by subcutaneous injection of methylated bovine serum albumin in sensitized animals. Mini‐osmotic pumps releasing human recombinant IL‐1 receptor antagonist (IL‐1ra) protein were implanted intraperitoneally 2 days before arthritis induction, and neutralizing antibodies directed against murine IL‐1α, IL‐1β, TNFα, or IL‐6 were administered 1 day before. Proteoglycan (PG) synthesis and degradation were assessed in patellar cartilage.
Results. Murine IL‐1α and IL‐1β injected intraarticularly at doses of 0.1–100 ng suppressed chondrocyte PG synthesis. The highest dose of TNF tested (100 ng) decreased PG synthesis marginally. In contrast, the maximum dose of IL‐6 (1 μg) stimulated PG synthesis 2 days after injection. Treatment of AIA with neutralizing monoclonal antibodies against either TNFα or IL‐6 did not reduce either the PG degradation or the suppression of its synthesis. However, treatment with anti‐IL‐1 (α + β) polyclonal antibodies totally prevented PG suppression, although the initial breakdown of PG was unaffected. This effect was confirmed when IL‐1ra was administered in high doses. Moreover, treatment of ZIA with anti‐IL‐1 (α + β), but not with anti‐TNF, resulted in normal PG synthesis, confirming the key role played by IL‐1 in the inhibition of PG synthesis. Treatment of AIA with anti‐IL‐1 did not affect inflammation during the acute phase, but a significant reduction of ongoing inflammation was noted at day 7, and there was a marked reduction in the loss of cartilage PG.
Conclusion. The suppression of PG synthesis in both ZIA and AIA in mice is due to the combined local action of IL‐1 (α + β), and neither IL‐6 nor TNF is involved. Moreover, the normalization of PG synthesis brought about by blocking of IL‐1 ameliorates the cartilage damage associated with AIA.</description><subject>Animals</subject><subject>Antibody Formation</subject><subject>Antigens</subject><subject>Arthritis - chemically induced</subject><subject>Arthritis - etiology</subject><subject>Arthritis - prevention & control</subject><subject>Biological and medical sciences</subject><subject>Cartilage, Articular - drug effects</subject><subject>Cartilage, Articular - metabolism</subject><subject>Cartilage, Articular - pathology</subject><subject>Cytokines - immunology</subject><subject>Diseases of the osteoarticular system</subject><subject>Inflammatory joint diseases</subject><subject>Interleukin-1 - physiology</subject><subject>Interleukin-6 - physiology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Proteoglycans - biosynthesis</subject><subject>Proteoglycans - metabolism</subject><subject>Receptors, Interleukin-1 - antagonists & inhibitors</subject><subject>Tumor Necrosis Factor-alpha - physiology</subject><subject>Zymosan</subject><issn>0004-3591</issn><issn>1529-0131</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUctuFDEQHCFQWAJXbkg-IE6ZxR6_xsco4iVFQorCeeT1tBeDxw62R2g55RPyK3wHEh_Bl-DJrgLiwskqd1VXdXfTPCV4TTDuXupU1kT2mPa4w-xesyK8Uy0mlNxvVhhj1lKuyMPmUc6fKuwop0fNkexZT7FYNT8uogcULXKhQPIwf3bh1_UNOUFlnmJCAUyK2WVktSkV__x-gnQY_6GLipGpUZzXW0BXKRaIW78zOqAJit5E7_J0KxwhlzSb4mJAYC2YsndH2ZUZbXw0teV2-Zjm5AJUUXFbWFxu9d92U8x6gS6Ms4ERVduPyRWXHzcPrPYZnhze4-bD61eXZ2_b8_dv3p2dnreGcs7anuNeSIb1RoDBm04IKzR0kikrGAVilGCWa6Io60yPTc-t1EKpcZRWYsLpcfNi37fO-WWu8wyTywa81wHinAciZFcXrypxvScuO8wJ7HCV3KTTbiB4WK431OzDn-tVwbND53kzwXhHP5yr1p8f6job7W3Swbh8R6NMScmXgGpP--o87P5jOpxeXP4V4Tdyl7vX</recordid><startdate>199502</startdate><enddate>199502</enddate><creator>Loo, Fons A. J. Van De</creator><creator>Joosten, Leo A. B.</creator><creator>Van Lent, Peter L. E. M.</creator><creator>Arntz, Onno J.</creator><creator>Van Den Berg, Wim B.</creator><general>John Wiley & Sons, Inc</general><general>Wiley</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>199502</creationdate><title>Role of interleukin‐1, tumor necrosis factor α, and interleukin‐6 in cartilage proteoglycan metabolism and destruction effect of in situ blocking in murine antigen‐ and zymosan‐induced arthritis</title><author>Loo, Fons A. J. Van De ; Joosten, Leo A. B. ; Van Lent, Peter L. E. M. ; Arntz, Onno J. ; Van Den Berg, Wim B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3554-85086740ab6ec0b266f6ae2749f643e1c964f5a19342c80c85f7a699dd7f70153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Animals</topic><topic>Antibody Formation</topic><topic>Antigens</topic><topic>Arthritis - chemically induced</topic><topic>Arthritis - etiology</topic><topic>Arthritis - prevention & control</topic><topic>Biological and medical sciences</topic><topic>Cartilage, Articular - drug effects</topic><topic>Cartilage, Articular - metabolism</topic><topic>Cartilage, Articular - pathology</topic><topic>Cytokines - immunology</topic><topic>Diseases of the osteoarticular system</topic><topic>Inflammatory joint diseases</topic><topic>Interleukin-1 - physiology</topic><topic>Interleukin-6 - physiology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Proteoglycans - biosynthesis</topic><topic>Proteoglycans - metabolism</topic><topic>Receptors, Interleukin-1 - antagonists & inhibitors</topic><topic>Tumor Necrosis Factor-alpha - physiology</topic><topic>Zymosan</topic><toplevel>online_resources</toplevel><creatorcontrib>Loo, Fons A. J. Van De</creatorcontrib><creatorcontrib>Joosten, Leo A. B.</creatorcontrib><creatorcontrib>Van Lent, Peter L. E. M.</creatorcontrib><creatorcontrib>Arntz, Onno J.</creatorcontrib><creatorcontrib>Van Den Berg, Wim B.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Arthritis and rheumatism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Loo, Fons A. J. Van De</au><au>Joosten, Leo A. B.</au><au>Van Lent, Peter L. E. M.</au><au>Arntz, Onno J.</au><au>Van Den Berg, Wim B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of interleukin‐1, tumor necrosis factor α, and interleukin‐6 in cartilage proteoglycan metabolism and destruction effect of in situ blocking in murine antigen‐ and zymosan‐induced arthritis</atitle><jtitle>Arthritis and rheumatism</jtitle><addtitle>Arthritis Rheum</addtitle><date>1995-02</date><risdate>1995</risdate><volume>38</volume><issue>2</issue><spage>164</spage><epage>172</epage><pages>164-172</pages><issn>0004-3591</issn><eissn>1529-0131</eissn><coden>ARHEAW</coden><abstract>Objective. To determine the involvement of interleukin‐1 (IL‐1), tumor necrosis factor (TNF), and IL‐6 in the cartilage pathology of murine antigen‐induced arthritis (AIA) and zymosan‐induced arthritis (ZIA).
Methods. Arthritis was induced by intraarticular injection of zymosan in naive mice or by subcutaneous injection of methylated bovine serum albumin in sensitized animals. Mini‐osmotic pumps releasing human recombinant IL‐1 receptor antagonist (IL‐1ra) protein were implanted intraperitoneally 2 days before arthritis induction, and neutralizing antibodies directed against murine IL‐1α, IL‐1β, TNFα, or IL‐6 were administered 1 day before. Proteoglycan (PG) synthesis and degradation were assessed in patellar cartilage.
Results. Murine IL‐1α and IL‐1β injected intraarticularly at doses of 0.1–100 ng suppressed chondrocyte PG synthesis. The highest dose of TNF tested (100 ng) decreased PG synthesis marginally. In contrast, the maximum dose of IL‐6 (1 μg) stimulated PG synthesis 2 days after injection. Treatment of AIA with neutralizing monoclonal antibodies against either TNFα or IL‐6 did not reduce either the PG degradation or the suppression of its synthesis. However, treatment with anti‐IL‐1 (α + β) polyclonal antibodies totally prevented PG suppression, although the initial breakdown of PG was unaffected. This effect was confirmed when IL‐1ra was administered in high doses. Moreover, treatment of ZIA with anti‐IL‐1 (α + β), but not with anti‐TNF, resulted in normal PG synthesis, confirming the key role played by IL‐1 in the inhibition of PG synthesis. Treatment of AIA with anti‐IL‐1 did not affect inflammation during the acute phase, but a significant reduction of ongoing inflammation was noted at day 7, and there was a marked reduction in the loss of cartilage PG.
Conclusion. The suppression of PG synthesis in both ZIA and AIA in mice is due to the combined local action of IL‐1 (α + β), and neither IL‐6 nor TNF is involved. Moreover, the normalization of PG synthesis brought about by blocking of IL‐1 ameliorates the cartilage damage associated with AIA.</abstract><cop>New York</cop><pub>John Wiley & Sons, Inc</pub><pmid>7848306</pmid><doi>10.1002/art.1780380204</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0004-3591 |
| ispartof | Arthritis and rheumatism, 1995-02, Vol.38 (2), p.164-172 |
| issn | 0004-3591 1529-0131 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_16720049 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection |
| subjects | Animals Antibody Formation Antigens Arthritis - chemically induced Arthritis - etiology Arthritis - prevention & control Biological and medical sciences Cartilage, Articular - drug effects Cartilage, Articular - metabolism Cartilage, Articular - pathology Cytokines - immunology Diseases of the osteoarticular system Inflammatory joint diseases Interleukin-1 - physiology Interleukin-6 - physiology Male Medical sciences Mice Proteoglycans - biosynthesis Proteoglycans - metabolism Receptors, Interleukin-1 - antagonists & inhibitors Tumor Necrosis Factor-alpha - physiology Zymosan |
| title | Role of interleukin‐1, tumor necrosis factor α, and interleukin‐6 in cartilage proteoglycan metabolism and destruction effect of in situ blocking in murine antigen‐ and zymosan‐induced arthritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T03%3A07%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20interleukin%E2%80%901,%20tumor%20necrosis%20factor%20%CE%B1,%20and%20interleukin%E2%80%906%20in%20cartilage%20proteoglycan%20metabolism%20and%20destruction%20effect%20of%20in%20situ%20blocking%20in%20murine%20antigen%E2%80%90%20and%20zymosan%E2%80%90induced%20arthritis&rft.jtitle=Arthritis%20and%20rheumatism&rft.au=Loo,%20Fons%20A.%20J.%20Van%20De&rft.date=1995-02&rft.volume=38&rft.issue=2&rft.spage=164&rft.epage=172&rft.pages=164-172&rft.issn=0004-3591&rft.eissn=1529-0131&rft.coden=ARHEAW&rft_id=info:doi/10.1002/art.1780380204&rft_dat=%3Cproquest_cross%3E16720049%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16720049&rft_id=info:pmid/7848306&rfr_iscdi=true |